Janus激酶抑制剂在皮肤病治疗中的应用前景

doi:10.35541/cjd.20190564

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (10): 845-848.doi: 10.35541/cjd.20190564

Janus激酶抑制剂在皮肤病治疗中的应用前景

李明周俐宏李邻峰

首都医科大学附属北京友谊医院皮肤科 100050

收稿日期:2019-05-09 修回日期:2020-01-21 发布日期:2020-09-30
通讯作者: 李邻峰 E-mail:zoonli@sina.com

Prospects of Janus kinase inhibitors in the treatment of skin diseases

Li Ming, Zhou Lihong, Li Linfeng

Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2019-05-09 Revised:2020-01-21 Published:2020-09-30
Contact: Li Linfeng E-mail:zoonli@sina.com

摘要/Abstract

摘要： 【摘要】 Janus激酶（JAK）和信号转导和转录激活因子（STAT）所构成的JAK-STAT信号通路是一条重要的细胞内信号通路，参与许多炎症性疾病的发病。JAK抑制剂阻断该通路已经成为治疗某些疾病的有效方法，例如类风湿关节炎、溃疡性结肠炎。然而，目前JAK抑制剂尚未被批准应用于皮肤病治疗。本文就JAK抑制剂在皮肤疾病中的应用前景进行综述。

关键词: Janus激酶类, 蛋白激酶抑制剂, 信号传导, 皮肤疾病, 炎症, 炎症性皮肤病, 治疗结果, 药物毒性

Abstract: 【Abstract】 The JAK-STAT signaling pathway, composed of Janus kinase (JAK) and signal transducer and activator of transcription (STAT), is an important intracellular signaling pathway. It is involved in the occurrence of many inflammatory diseases. Blocking this pathway by JAK inhibitors has become an effective approach to the treatment of some diseases, such as rheumatoid arthritis and ulcerative colitis. However, JAK inhibitors have not been approved for the treatment of skin diseases at present. This review summarizes application prospects of JAK inhibitors in the treatment of skin diseases.

Key words: Janus kinases, Protein kinase inhibitors, Signal transduction, Skin diseases, Inflammation, Inflammatory dermatosis, Treatment outcome, Drug toxicity

李明周俐宏李邻峰. Janus激酶抑制剂在皮肤病治疗中的应用前景[J]. 中华皮肤科杂志, 2020,53(10):845-848. doi:10.35541/cjd.20190564

Li Ming, Zhou Lihong, Li Linfeng. Prospects of Janus kinase inhibitors in the treatment of skin diseases[J]. Chinese Journal of Dermatology, 2020, 53(10): 845-848.doi:10.35541/cjd.20190564

参考文献 32

［1］	Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease［J］. Nat Rev Rheumatol, 2017,13（4）:234⁃243. doi: 10.1038/nrrheum.2017.23.
［2］	Ciechanowicz P, Rakowska A, Sikora M, et al. JAK⁃inhibitors in dermatology: current evidence and future applications［J］. J Dermatolog Treat, 2019,30（7）:648⁃658. doi: 10.1080/09546634. 2018.1546043.
［3］	杨玉慧, 许秀丽, 张波. 治疗类风湿性关节炎新药托法替布［J］. 临床药物治疗杂志, 2018,16（12）:53⁃56,60. doi: 10.3969/j.issn.1672⁃3384.2018.12.013.
［4］	Morelli M, Scarponi C, Mercurio L, et al. Selective immunomodulation of inflammatory pathways in keratinocytes by the Janus kinase （JAK） inhibitor tofacitinib: implications for the employment of JAK⁃Targeting drugs in psoriasis［J］. J Immunol Res, 2018,2018:7897263. doi: 10.1155/2018/7897263.
［5］	Strober BE, Gottlieb AB, van de Kerkhof P, et al. Benefit⁃risk profile of tofacitinib in patients with moderate⁃to⁃severe chronic plaque psoriasis: pooled analysis across six clinical trials［J］. Br J Dermatol, 2019,180（1）:67⁃75. doi: 10.1111/bjd.17149.
［6］	Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
［7］	Valenzuela F, Paul C, Mallbris L, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient⁃reported outcomes from a Phase 3 study［J］. J Eur Acad Dermatol Venereol, 2016,30（10）:1753⁃1759. doi: 10.1111/jdv.13702.
［8］	Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis［J］. Br J Dermatol, 2013,169（1）:137⁃145. doi: 10.1111/bjd.12266.
［9］	Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial［J］. BMC Dermatol, 2016,16（1）:15. doi: 10.1186/s12895⁃016⁃0051⁃4.
［10］	He H, Guttman⁃Yassky E. JAK inhibitors for atopic dermatitis: an update［J］. Am J Clin Dermatol, 2019,20（2）:181⁃192. doi: 10.1007/s40257⁃018⁃0413⁃2.
［11］	Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate［J］. J Am Acad Dermatol, 2015,73（3）:395⁃399. doi: 10.1016/j.jaad.2015.06.045.
［12］	Guttman⁃Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate⁃to⁃severe atopic dermatitis: a phase 2 parallel, double⁃blinded, randomized placebo⁃controlled multiple⁃dose study［J］. J Am Acad Dermatol, 2019,80（4）:913⁃921.e9. doi: 10.1016/j.jaad.2018.01.018.
［13］	Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial［J］. Br J Dermatol, 2016,175（5）:902⁃911. doi: 10.1111/bjd.14871.
［14］	Wang Y, Li S, Li C. Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity［J］. Med Sci Monit, 2019,25:1017⁃1023. doi: 10.12659/MSM. 914898.
［15］	Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.
［16］	Kim SR, Heaton H, Liu LY, et al. Rapid repigmentation of vitiligo using tofacitinib plus low⁃dose, narrowband UV⁃B phototherapy［J］. JAMA Dermatol, 2018,154（3）:370⁃371. doi: 10.1001/jamadermatol.2017.5778.
［17］	Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA）［J］. J Am Acad Dermatol, 2016,74（2）:370⁃371. doi: 10.1016/j.jaad.2015.09.073.
［18］	Gianfaldoni S, Tchernev G, Wollina U, et al. Micro ⁃ focused phototherapy associated to janus kinase inhibitor: a promising valid therapeutic option for patients with localized vitiligo［J］. Open Access Maced J Med Sci, 2018,6（1）:46⁃48. doi: 10.3889/oamjms.2018.042.
［19］	Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682.e1. doi: 10.1016/j.jaad.2017.05.043.
［20］	Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib［J］. J Am Acad Dermatol, 2017,76（6）:1054⁃1060.e1. doi: 10.1016/j.jaad. 2017.02.049.
［21］	Joshipura D, Alomran A, Zancanaro P, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32⁃week open⁃label extension study with optional narrow⁃band ultraviolet B［J］. J Am Acad Dermatol, 2018,78（6）:1205⁃1207.e1. doi: 10. 1016/j.jaad.2018.02.023.
［22］	Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition［J］. Nat Med, 2014,20（9）:1043⁃1049. doi: 10.1038/nm.3645.
［23］	Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata［J］. JCI Insight, 2016,1（15）:e89776. doi: 10.1172/jci.insight.89776.
［24］	Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（2）:566⁃568. doi: 10. 1016/j.jaad.2018.08.040.
［25］	Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open⁃label comparative study［J］. Dermatology, 2019,235（2）:130⁃136. doi: 10.1159/000494613.
［26］	余丽娟, 吕中法. JAK抑制剂治疗斑秃的研究进展［J］. 中华皮肤科杂志, 2019,52（5）:343⁃346. doi: 10.3760/cma.j.issn.0412⁃4030.2019.05.014.
［27］	Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients［J］. J Am Acad Dermatol, 2018,78（2）:403⁃404.e1. doi: 10.1016/j.jaad.2017.10.043.
［28］	Putterman E, Castelo⁃Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis［J］. J Am Acad Dermatol, 2018,78（6）:1207⁃1209.e1. doi: 10.1016/j.jaad.2018.02.031.
［29］	Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib［J］. J Am Acad Dermatol, 2017,77（2）:302⁃309. doi: 10.1016/j.jaad.2017.03.023.
［30］	Curtis JR, Lee EB, Martin G, et al. Analysis of non⁃melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme［J］. Clin Exp Rheumatol, 2017,35（4）:614⁃622.
［31］	Xie W, Huang Y, Xiao S, et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta⁃analysis of randomised controlled trials［J］. Ann Rheum Dis, 2019,78（8）:1048⁃1054. doi: 10.1136/annrheumdis⁃2018⁃214846.
［32］	Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment［J］. JAMA Dermatol, 2016,152（8）:944⁃945. doi: 10.1001/jamadermatol. 2016.0866.

[1]	姚玲玲, 余增洋郭春源周静崔莲于倩虞英媛周雪蔡江鲁伊史玉玲, . 节律基因隐花色素2在银屑病小鼠模型及HaCaT细胞中的表达变化及机制研究[J]. 中华皮肤科杂志, 2022, 55(9): 759-766.
[2]	晋亮刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739.
[3]	徐哲. 对遗传性皮肤病的一些思考[J]. 中华皮肤科杂志, 2022, 55(8): 651-652.
[4]	魏瑾臧东杰曾三武蒋靖伦文辉. Dowling-Degos病1家系KRT5基因新突变分析[J]. 中华皮肤科杂志, 2022, 55(8): 703-705.
[5]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[6]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[7]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[8]	黄馨陈筱昀李亚萍梁兴堃张桂英周英湛意罗帅寒天廖洁月肖嵘龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493.
[9]	闪莹左亚刚. 自身免疫性疱病与银屑病的相关性[J]. 中华皮肤科杂志, 2022, 55(5): 452-455.
[10]	胡烨蓓宋秀祖. 氨甲环酸治疗黄褐斑的研究进展[J]. 中华皮肤科杂志, 2022, 55(5): 460-462.
[11]	李丹琪楼雨晨陶娟. 大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展[J]. 中华皮肤科杂志, 2022, 55(5): 455-459.
[12]	李巍尹慧彬. 特应性皮炎的部位异质性[J]. 中华皮肤科杂志, 2022, 55(4): 349-352.
[13]	李妍李明徐薇李邻峰. 【开放获取】凯普斯泰冷敷凝胶治疗成人轻中度特应性皮炎的随机双盲对照研究[J]. 中华皮肤科杂志, 2022, 55(4): 345-348.
[14]	刘擘宋晓婷廖双璐于淼栾婷婷李若瑜赵作涛. 【开放获取】巴瑞替尼治疗中重度特应性皮炎的疗效和安全性观察[J]. 中华皮肤科杂志, 2022, 55(4): 304-307.
[15]	刘擘宋晓婷李若瑜赵作涛. 【开放获取】度普利尤单抗治疗特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 295-298.

Janus激酶抑制剂在皮肤病治疗中的应用前景

Prospects of Janus kinase inhibitors in the treatment of skin diseases

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

Metrics

本文评价

推荐阅读 10